Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZhong ZhengSCShu ChengWZWei Zhao

Discussion

Loading...

Member takes

Overview

Phase II study shows 89% overall response in newly diagnosed follicular lymphoma patients, suggesting a promising treatment strategy.

Key Points

  • Complete response rate reached 67.8% among evaluable patients with advanced follicular lymphoma.
  • Overall response rate at 89.3% indicates high effectiveness of the treatment regimen over six induction cycles.
  • Trial involved treatment-naïve patients with elevated LDH and multiple extranodal sites, ages 28 to 78.
  • Exploration of the therapeutic mechanism may enhance future treatment protocols for high-risk follicular lymphoma.

Cite This Study

Zheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d714https://doi.org/10.1182/blood-2025-7123
View Full Paper
Ask AI
Bookmark
Share